Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide.

Strains of Enterobacteriaceae producing an extended spectrum beta-lactamase have become a concern in medical bacteriology as regards both antimicrobial treatment and infection control in hospitals. Extended-spectrum beta-lactamase (ESBL) detection tests should accurately discriminate between bacteria producing these enzymes and those with other mechanisms of resistance to beta-lactams, e.g., broad-spectrum beta-lactamases, inhibitor-resistant beta-lactamases and cephalosporinase overproduction. Several phenotypic detection tests, based on the synergy between a third-generation cephalosporin and clavulanate, have been designed: the double-disk synergy test (DDST), ESBL Etests, and the combination disk method. These tests often need to be refined in order for them to detect an ESBL in some bacterial strains, such as those that also overproduce a cephalosporinase. The sensitivity of the DDST can be improved by reducing the distance between the disks of cephalosporins and clavulanate. The use of cefepime, a fourth-generation cephalosporin that is less rapidly inactivated by cephalosporinase than by ESBL, improves the detection of synergy with clavulanate when there is simultaneous stable hyperproduction of a cephalosporinase; alternatively, the cephalosporinase can be inactivated by performing phenotypic tests on a cloxacillin-containing agar. Some beta-lactamases can hydrolyse both third-generation cephalosporins and carbapenems, such as the metallo-beta-lactamases, which are not inhibited by clavulanate, but rather by EDTA. The production of an ESBL masked by a metallo-beta-lactamase can be detected by means of double inhibition by EDTA and clavulanate. Since extended-spectrum Ambler class D oxacillinases are weakly inhibited by clavulanate and not inhibited by EDTA, their detection is difficult in the routine laboratory.

[1]  Victor L. Yu,et al.  Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β-Lactamases: Implications for the Clinical Microbiology Laboratory , 2001, Journal of Clinical Microbiology.

[2]  P. Shah,et al.  Escherichia coli and Klebsiella pneumoniae strains more susceptible to cefoxitin than to third generation cephalosporins. , 1983, The Journal of antimicrobial chemotherapy.

[3]  P. Hawkey,et al.  Detection of extended-spectrum beta-lactamases in members of the family enterobacteriaceae: comparison of the MAST DD test, the double disc and the Etest ESBL. , 2000, The Journal of antimicrobial chemotherapy.

[4]  M. Cormican,et al.  Detection of extended-spectrum beta-lactamase (ESBL)-producing strains by the Etest ESBL screen , 1996, Journal of clinical microbiology.

[5]  D. Zhou,et al.  Detection of Extended-Spectrum β-Lactamases in Clinical Isolates of Pseudomonas aeruginosa , 2006, Antimicrobial Agents and Chemotherapy.

[6]  S. Chun,et al.  Development of DNA chip for the simultaneous detection of various beta-lactam antibiotic-resistant genes. , 2002, Molecules and cells.

[7]  G. Paul,et al.  Dissemination in five French hospitals ofKlebsiella pneumoniae serotype K25 harbouring a new transferable enzymatic resistance to third generation cephalosporins and aztreonam , 1988, European Journal of Clinical Microbiology and Infectious Diseases.

[8]  A. Tsakris,et al.  Detection of Extended-Spectrum β-Lactamases in Clinical Isolates of Enterobacter cloacae andEnterobacter aerogenes , 2000, Journal of Clinical Microbiology.

[9]  R. Cluzel,et al.  Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase. , 1987, The Journal of antimicrobial chemotherapy.

[10]  V. Jarlier,et al.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. , 1988, Reviews of infectious diseases.

[11]  P. Bradford Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat , 2001, Clinical Microbiology Reviews.

[12]  P. Nordmann,et al.  Metallo-beta-lactamases: the quiet before the storm? , 2005, Clinical microbiology reviews.

[13]  D. Livermore,et al.  OXA-17, a Further Extended-Spectrum Variant of OXA-10 β-Lactamase, Isolated from Pseudomonas aeruginosa , 1999, Antimicrobial Agents and Chemotherapy.

[14]  P. Nordmann,et al.  Outbreak of Extended-Spectrum β-Lactamase VEB-1-Producing Isolates of Acinetobacter baumannii in a French Hospital , 2003, Journal of Clinical Microbiology.

[15]  Armand Paauw,et al.  Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 Automated Instruments for Detection of Extended-Spectrum Beta-Lactamases in Multiresistant Escherichia coli and Klebsiella spp , 2002, Journal of Clinical Microbiology.

[16]  E. Kim,et al.  Bloodstream Infections by Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in Children: Epidemiology and Clinical Outcome , 2002, Antimicrobial Agents and Chemotherapy.

[17]  A L Barry,et al.  Detection of extended-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test , 1996, Journal of clinical microbiology.

[18]  A. Bolmström,et al.  Evaluation of a New Etest for Detecting Metallo-β-Lactamases in Routine Clinical Testing , 2002, Journal of Clinical Microbiology.

[19]  Robert A. Bonomo,et al.  Extended-Spectrum (cid:2) -Lactamases: a Clinical Update , 2005 .

[20]  W. Sougakoff,et al.  Plasmid-mediated resistance to third-generation cephalosporins caused by point mutations in TEM-type penicillinase genes. , 1988, Reviews of infectious diseases.

[21]  Harald Seifert,et al.  Detection of Extended-Spectrum Beta-Lactamases among Enterobacteriaceae by Use of Semiautomated Microbiology Systems and Manual Detection Procedures , 2007, Journal of Clinical Microbiology.

[22]  P. Nordmann,et al.  OXA-type beta-lactamases. , 1999, Current pharmaceutical design.

[23]  Patrick Legrand,et al.  TRANSFERABLE ENZYMATIC RESISTANCE TO THIRD-GENERATION CEPHALOSPORINS DURING NOSOCOMIAL OUTBREAK OF MULTIRESISTANT KLEBSIELLA PNEUMONIAE , 1987, The Lancet.

[24]  H. Shin,et al.  Imipenem-EDTA Disk Method for Differentiation of Metallo-β-Lactamase-Producing Clinical Isolates of Pseudomonas spp. and Acinetobacter spp , 2002, Journal of Clinical Microbiology.

[25]  Timothy R. Walsh,et al.  Metallo-β-Lactamases: the Quiet before the Storm? , 2005, Clinical Microbiology Reviews.

[26]  J. Rickman,et al.  Guilt and dynamics of psychological disorder. , 1948, Lancet.

[27]  D. Livermore,et al.  Detection of Extended-Spectrum β-Lactamases in Klebsiellae with the Oxoid Combination Disk Method , 2000, Journal of Clinical Microbiology.

[28]  G. Barnaud,et al.  Salmonella enteritidis: AmpC Plasmid-Mediated Inducible β-Lactamase (DHA-1) with anampR Gene from Morganella morganii , 1998, Antimicrobial Agents and Chemotherapy.

[29]  A. Linscott,et al.  Evaluation of Four Commercially Available Extended-Spectrum Beta-Lactamase Phenotypic Confirmation Tests , 2005, Journal of Clinical Microbiology.

[30]  Kenneth S. Thomson,et al.  Comparison of Phoenix and VITEK 2 Extended-Spectrum-β-Lactamase Detection Tests for Analysis of Escherichia coli and Klebsiella Isolates with Well-Characterized β-Lactamases , 2007, Journal of Clinical Microbiology.

[31]  J. Duval,et al.  Detection of extended broad-spectrum beta-lactamases inEnterobacteriaceae in four French hospitals , 1989, European Journal of Clinical Microbiology and Infectious Diseases.

[32]  A. Tsakris,et al.  Detection of extended-spectrum beta-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. , 2000, Journal of clinical microbiology.

[33]  G. Paul,et al.  [Enterobacter cloacae. In vivo emergence of a variant resistant to new beta-lactams during treatment with lamoxactam-gentamicin]. , 1984, Pathologie-biologie.

[34]  B. Wiedemann,et al.  Evolution of plasmid-coded resistance to broad-spectrum cephalosporins , 1985, Antimicrobial Agents and Chemotherapy.

[35]  S. Mitsuhashi,et al.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens , 1983, Infection.

[36]  R. Schmid,et al.  Use of DNA Microarrays for Rapid Genotyping of TEM Beta-Lactamases That Confer Resistance , 2004, Journal of Clinical Microbiology.

[37]  D. Samuel,et al.  First outbreak of multidrug-resistant Klebsiella pneumoniae carrying blaVIM-1 and blaSHV-5 in a French university hospital. , 2006, The Journal of antimicrobial chemotherapy.

[38]  K. Thomson,et al.  Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests , 1992, Antimicrobial Agents and Chemotherapy.

[39]  Y. Arakawa,et al.  Convenient Test for Screening Metallo-β-Lactamase-Producing Gram-Negative Bacteria by Using Thiol Compounds , 2000, Journal of Clinical Microbiology.

[40]  Maurizio Sanguinetti,et al.  Characterization of Clinical Isolates of Enterobacteriaceae from Italy by the BD Phoenix Extended-Spectrum β-Lactamase Detection Method , 2003, Journal of Clinical Microbiology.

[41]  Yehuda Carmeli,et al.  Utility of the VITEK 2 Advanced Expert System for Identification of Extended-Spectrum β-Lactamase Production in Enterobacter spp , 2006, Journal of Clinical Microbiology.